GM-2505

Bretisilocin (formerly GM-2505) is a short-duration intravenous 5-HT2A receptor agonist and serotonin releaser developed by Gilgamesh Pharmaceuticals for major depressive disorder (MDD) and acquired by AbbVie in October 2025 [1][2][10]. The randomized, double-blind Phase 2a study (NCT06236880) reported topline results in May 2025 showing a 21.6 point reduction on the Montgomery-Asberg Depression Rating Scale (MADRS, a 60 point clinician-rated depression severity scale where a change of roughly 10 points is considered clinically meaningful and remission is a score at or below 10) on the 10 mg arm versus 12.1 points on the 1 mg active low-dose comparator arm (p=0.003), with 70 percent of high-dose patients in remission at Day 14 and 94 percent in remission at Day 29 after a second 15 mg dose [3][11]. The commercial thesis is now partially de-risked: deliver a psilocybin-style antidepressant effect in a session short enough to fit inside a normal outpatient visit, backed by data that AbbVie was willing to pay up to $1.2 billion for [4][10].

Investigational compound, not approved anywhere. Phase 2a in MDD is complete with positive topline efficacy data published in May 2025 (n=40 evaluated for efficacy in the reported segment, total enrollment across Parts A, B, and C listed at 126 on the registry) [3][11]. Key results on the 10 mg arm at Day 14: MADRS change from baseline of -21.6 versus -12.1 on the 1 mg active comparator (p=0.003, estimated effect size 1.0), 70 percent remission (MADRS score at or below 10), rapid onset (-18.5 at 24 hours), and durability sustained to Day 74 without additional treatment; on Day 29 after a second 15 mg dose the high-dose group reached -28.0 MADRS change from baseline and 94 percent remission [11]. Marek and colleagues published the healthy-volunteer PK, safety, and pharmacodynamic profile in the Journal of Psychopharmacology in 2026, establishing that a single IV dose produces a psychedelic experience with a duration measured in tens of minutes rather than hours [2]. AbbVie announced the acquisition on August 25, 2025 and closed it on October 17, 2025 for up to $1.2 billion total (upfront and development milestones; the upfront/milestone split has not been publicly disclosed in the press releases or in AbbVie's initial 8-K exhibit) [4][10]. Gilgamesh spun out a new entity, Gilgamesh Pharma Inc., to retain other pipeline programs. No FDA breakthrough therapy, fast-track, or orphan designation has been publicly disclosed. Next expected inflection is AbbVie's disclosure of Phase 2b design, powering, and timeline, plus any regulatory interaction summary post-acquisition.

Serotonin is a signaling chemical the brain uses for mood, perception, and cognition. The 5-HT2A receptor is one of about a dozen serotonin receptors, and it sits on cortical neurons where it appears to gate synaptic plasticity, the process by which brain connections rewire in response to experience [6]. Classical psychedelics (psilocybin, LSD, DMT) all agonize this receptor, and a single dose produces changes in mood and self-perception that outlast the drug itself by weeks. Bretisilocin adds a second mechanistic lever: it is both a 5-HT2A agonist and a serotonin releaser, meaning it increases extracellular serotonin in a manner more reminiscent of MDMA-adjacent entactogens than of pure receptor agonists like psilocybin, and this dual action may compound the acute antidepressant effect [2][10]. The mechanism is well-validated at the target level: Open Targets scores HTR2A at 0.70 for MDD, and atypical antipsychotics used in MDD augmentation (quetiapine, risperidone) already act on this receptor as antagonists [7]. The novel part is the agonist approach for depression, not the target itself. The central scientific question for the short-duration angle is whether the extended six-to-eight-hour psychological journey seen with psilocybin is mechanistically required for the durable antidepressant effect (the BDNF and dendritic-spine plasticity hypothesis, in which the trip is a necessary state for the biological rewiring to consolidate) or whether acute 5-HT2A activation is itself sufficient to trigger the plasticity, with the subjective experience being downstream and dispensable. The Phase 2a data are the first empirical evidence that compressing the session to roughly 30 to 60 minutes preserves the efficacy: a -21.6 MADRS delta with durability out to Day 74 is not a compromised signal, it is a competitive one. That is the scientifically informative result inside this readout.

NCT06236880 is a Phase 2a study in adults with MDD, structured in three parts (A, B, C) with safety and tolerability as the primary endpoint and MADRS-based efficacy as key secondary and exploratory measures [3]. Enrollment target of 126 has been met and the trial is listed as completed. Critically, the study was randomized, double-blind, and used a 1 mg low-dose active comparator arm of bretisilocin itself as the control (not open-label as an early misread of the registry might suggest); this design is specifically responsive to the FDA's functional-unblinding critique from the August 2024 Lykos CRL, because both arms produce some subjective drug effect and neither is an inert placebo [9][11]. Part A recruited patients not currently on antidepressants, which is the right design choice for a first look at psychedelic efficacy because SSRIs are known to blunt 5-HT2A response and would confound the signal. Design limitations remain: n=40 in the efficacy segment is small, the low-dose comparator is a compromise between blinding integrity and pure placebo control, and generalization to SSRI-treated or treatment-resistant populations is not yet supported by the current dataset. The Marek et al healthy-volunteer paper established the dose-response and duration profile that Part B and C were calibrated against [2]. What Phase 2b will need to answer: replication in a larger patient set, performance against inert placebo or an established active comparator, response in SSRI-experienced or treatment-resistant depression (TRD, typically defined as failure of at least two prior antidepressant trials at adequate dose and duration), and durability past three months.

Our model estimates a 4% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 24%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is held back by heavier-than-usual blinding, the sponsor's thin or weak approval record, weak or limited earlier-phase results, and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk has been meaningfully reduced by the Phase 2a readout but not eliminated. Compass Pathways' Phase 3 COMP005 in treatment-resistant depression missed on primary endpoint at some analysis timepoints and hit at others, which is a warning shot for the entire class: psychedelic antidepressant effects may be real but hard to demonstrate against active placebo in properly blinded regulatory-grade trials [4]. Bretisilocin's Phase 2a used a low-dose active comparator that produces some subjective effect, which is stronger blinding than pure placebo would allow but is not a full test of whether the effect holds against an inert control. Safety risk is class-mechanistic. 5-HT2A agonism produces acute hallucinations, dissociation, and blood pressure spikes; any cross-reactivity with 5-HT2B (implicated in valvular heart disease with fenfluramine and cabergoline) would be a program-killer, and selectivity data for bretisilocin has not been publicly disclosed in detail. Regulatory risk was reset by the August 2024 FDA complete response letter to Lykos Therapeutics on MDMA-assisted therapy, which flagged trial blinding, functional unblinding, and abuse-liability assessment as sector-wide concerns any psychedelic sponsor now has to address [9]. Commercial risk: even a clean approval would land into a Risk Evaluation and Mitigation Strategy (REMS, an FDA-required program that constrains distribution and dosing of high-risk drugs) requiring supervised in-clinic administration, and payer coverage for a single-dose psychiatric intervention with a monitoring cost stack has no clean analogue in current MDD reimbursement. Investor risk: patent and market exclusivity window for bretisilocin has not been publicly disclosed, and any thin exclusivity horizon would compress AbbVie's return runway on a $1.2 billion commitment.

De-risked meaningfully by the Phase 2a data, now a strategic AbbVie psychiatry asset rather than a speculative biotech bet. The signal to watch is no longer the Phase 2a readout (it has landed and it is strong: -21.6 MADRS at Day 14 on 10 mg, 94 percent remission at Day 29, durability to Day 74) but rather AbbVie's disclosure of Phase 2b design, powering, patient population (MDD versus TRD), comparator choice (inert placebo versus low-dose active), and timeline [10][11]. The most direct comparator in the class is Small Pharma's SPL026, also IV, also short-duration, also 5-HT2A-directed (via DMT); SPL026's Phase 2a reported a 57 percent remission rate at three months on a single dose in n=34, which is a solid signal but not as fast, deep, or high-remission as bretisilocin's early data at Day 14 and Day 29, and Small Pharma's program has not attracted a comparable big-pharma acquisition to date [12]. The $1.2 billion deal ceiling is the cleanest market-derived read on what a large sponsor with a real late-stage psychiatry organization thinks the Phase 3 asymptote is worth, and it validates the short-duration psychedelic thesis at a scale the class has not previously seen. Watch items: patent and exclusivity disclosure (undisclosed and material for AbbVie's return math), any Phase 2b protocol on ClinicalTrials.gov, cardiovascular safety data as the dataset grows, and the Compass COMP006 readout which will set the class-level regulatory tone for whether a 5-HT2A agonist can win a Phase 3 in depression against modern trial standards [4].